Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;101(4):450-452.
doi: 10.1002/cpt.590. Epub 2017 Feb 22.

Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy

Affiliations

Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy

K C Chua et al. Clin Pharmacol Ther. 2017 Apr.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity experienced in 30-40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The precision medicine approach incorporates both genome-wide association studies and functional models to understand the molecular mechanisms underlying CIPN with the goal of discovering novel strategies to prevent and treat this dose-limiting toxicity. The identification of genetic biomarkers will enable screening for CIPN risk, thereby improving clinical decisions. In vitro models to study CIPN have the potential to inform how patient susceptibility develops, identify novel therapeutic strategies for treatment and prevention, and test new chemical entities for liability for this toxicity.

Similar articles

Cited by

References

    1. Hershman DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers?: American Society of Clinical Oncology Clinical Practice Guideline. 2014 - PubMed
    1. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol. Oncol. 2016;140:176–183. - PMC - PubMed
    1. Baldwin RM, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 2012;18:5099–5109. - PMC - PubMed
    1. Sprowl JA, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. U. S. A. 2013;110:11199–11204. - PMC - PubMed
    1. Wheeler HE, Wing C, Delaney SM, Komatsu M, Dolan ME. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One. 2015;10:e0118020. - PMC - PubMed

Publication types

MeSH terms

Substances